ARL13B and Bardet-Biedl syndrome: Given the involvement of CFAP418 in BBS pathogenesis (9, 12, 13), we performed semiquantitative immunoblot analysis for BBS2, BBS4, and ARL13B, for which commercial antibodies are available.